Rare Voices Australia Ltd. / Conclusion Rare Voices Australia / /
Continent
Europe / /
Country
United States / Australia / United Kingdom / /
Event
Analyst Recommendation / /
Facility
Murdoch University / /
IndustryTerm
appropriate medical devices / therapies for that particular disease / pharmaceutical industry / Internet-based architecture / mortgage insurance / open source Internet-based disease registry system / care for rare disease / healthcare / therapeutic products / social services / appropriate quality healthcare / medicinal products / /
MedicalCondition
particular disease / rare diseases / Australian rare disease / disease / non-rare disease / rare disease / control diseases / sickness / chronically debilitating disease / international rare disease / Internet-based rare disease / specific rare diseases / diseases / disorder / rare and ultra-rare disease / open source Internet-based disease / /
MedicalTreatment
alternative therapies / /
Organization
National Alliance / Dept of Health / Social Committee / United Nations / LSDP Review Committee / Murdoch University / office of Population Health Genomics / National Organisation of Rare Disorders / European Commission / Australian Government / European Economic and Social Committee / European Parliament / Pharmaceutical Benefits Division / Department of Health / Department of Health GPO Box / European Organisation of Rare Diseases / Wellcome Trust / /
Life Saving Drugs Program Post Market-Review Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health GPO Box 9848, Canberra ACT[removed]November 2014 Dear Life Saving Drug Program Post-ma